<DOC>
	<DOCNO>NCT02513394</DOCNO>
	<brief_summary>This prospective , two arm , international , multicenter , randomize , open-label Phase III study evaluate addition 2 year palbociclib standard adjuvant endocrine therapy patient HR+ / HER2- early breast cancer ( EBC ) . The purpose PALLAS study determine whether addition palbociclib adjuvant endocrine therapy improve outcome endocrine therapy alone HR+/HER2- early breast cancer . Assessment variety correlative analysis , include evaluation effect palbociclib genomically define tumor subgroup , plan .</brief_summary>
	<brief_title>PALbociclib CoLlaborative Adjuvant Study : A Randomized Phase III Trial Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone Hormone Receptor Positive ( HR+ ) / Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Negative Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Signed informed consent prior study specific procedure . Age ≥18 year ( per national guideline ) . Pre postmenopausal woman men Stage II ( Stage IIA limit max . 1000 patient ) Stage III early invasive breast cancer Patients multicentric and/or multifocal and/or bilateral early invasive breast cancer eligible histopathologically examine tumor meet pathologic criterion ER+ and/or PR+ HER2 . Patients must histologically confirm ER+ and/or PR+ , HER2 , early invasive breast cancer . Patients must undergo breast surgery current malignancy . FFPE tumor tissue block must confirm received central sample repository prior randomization . ECOG performance status 01 . Patients must able willing swallow retain oral medication . Serum urine pregnancy test must negative premenopausal woman within 14 day randomization , woman amenorrhea less 12 month time randomization . Patients receive neo/adjuvant therapy must last dose chemotherapy and/or biologic therapy must sufficient resolution side effect . Patients receive breast/axilla/postmastectomy chest wall radiotherapy must last dose radiotherapy must sufficient resolution side effect . Patients must sufficient resolution surgical side effect ( active wound heal complication ) . Patients must either initiate already start adjuvant hormonal treatment . Patients already receive neo/adjuvant endocrine therapy eligible long enrol within 12 month initial histological diagnosis complete 6 month adjuvant endocrine therapy . Absolute neutrophil count ≥ 1,500/µL Platelets ≥ 100,000/ mm3 Hemoglobin ≥ 10g/dL Total serum bilirubin ≤ ULN ; total bilirubin ≤ 3.0 × ULN direct bilirubin within normal range patient document Gilbert 's Syndrome . Aspartate amino transferase ( AST SGOT ) alanine amino transferase ( ALT SGPT ) ≤ 1.5 × institutional ULN . Serum creatinine within normal institutional limit creatinine clearance ≥ 60 mL/min/1.73 m2 patient serum creatinine level institutional ULN . Concurrent therapy Investigational Products . Prior therapy CDK inhibitor . Patients Stage I IV breast cancer eligible . History allergic reaction attribute compound chemical biologic composition similar palbociclib . Patients receive medication substance potent inhibitor inducer CYP3A isoenzymes within 7 day randomization . Uncontrolled intercurrent illness would limit compliance study requirement . Pregnant woman , woman childbearing potential without negative pregnancy test within 14 day prior randomization . Patients history malignancy ineligible ( exception see : Pallas Protocol , v1.0 , Exclusion criteria 8 ) . Patients previously receive endocrine therapy within 5 year prior diagnosis current malignancy . Patients combination antiretroviral therapy . Patients clinically significant history liver disease . Patients receive concurrent exogenous hormone therapy ( topical vaginal estrogen therapy allowable ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HR+/HER2- breast cancer</keyword>
	<keyword>Palbociclib</keyword>
</DOC>